Name: FDA Catalyst: Example Drug
Start: 2026

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

PBPropanc Biopharma, Inc.

$1.17

+0.15 (+14.71%)

Market Cap

2.67 M

EPS

-33.19

P/E Ratio

Value Trade

25.91 K

SEC Financials

Q1 2026

Dilution Risk
95%
R&D Expenses
169.66 K

Total Assets
14.33 M
Total Liabilities
3.51 M
Equity
9.83 M

18.18 %

Week

-37.77 %

1 Month

-53.66 %

3 Month

-75.5 %

6 Month

-100 %

5 Year

-100 %

All Time

Cash Data

Critical

Cash Position
443.70 K
Monthly Burn
2.13 M
Runway
0 mo
Burn Trend
Accelerating
SEC Filing
May 14, 2026

Overview

Volume

247.09 K

52 Week Range

0.95 - 234

% held by Insiders

10.46 %

% held by Institutions

0.53 %

Enterprise Value

2.38 M

Total Shares

2.28 M

Short %

8.2 %

Float Shares

1.63 M

Company Description

HQ: 302/6 BUTLER STREET, CAMBERWEL...

Employees:2

https://www.propanc.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology

Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Propanc Biopharma, Inc.

61Total events

3Upcoming

4Tier-1 (high impact)

2014 – 2027Coverage

Upcoming catalysts 2

TBD

T3Manufacturing Milestone

Subscribe to view catalyst details

PRP

TBD

T2Trial Initiation

Subscribe to view catalyst details

PRP

Event history 2

TBD

●PublicationPresentation

Subscribe to view catalyst details

TBD

●Development Candidate NominationRec-PRPPreclinical

Subscribe to view catalyst details

Unlock the full Catalyst Timeline

Past FDA Catalysts & PDUFA Decisions

Date	Drug	Catalyst	Stage	Outcome	Reaction	Event Move %	Best Trade %
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%

Unlock Historical Catalyst data

Drug Pipeline Intelligence

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
Example Drug	Example indication for clinical evaluation	Phase 3	2025-12-01	The study met its primary endpoint demonstrating statistically significant improvement. Read More	Phase 3 Study Results Announcement
Example Drug	Example indication for clinical evaluation	Phase 3	2025-12-01	The study met its primary endpoint demonstrating statistically significant improvement. Read More	Phase 3 Study Results Announcement
Example Drug	Example indication for clinical evaluation	Phase 3	2025-12-01	The study met its primary endpoint demonstrating statistically significant improvement. Read More	Phase 3 Study Results Announcement

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in PPCB

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

PPCB Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Company News

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Propanc Biopharma has completed the first $500,000 tranche of its $5 million share repurchase program. The company aims to enhance shareholder value as it prepares for a Phase 1b study involving 40-45 advanced cancer patients. CEO James Nathanielsz emphasized the potential of their lead product, PRP, to transform metastatic cancer into a manageable condition.

-PPCB

Jul 21, 2026

PPCBGeneral

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Propanc Biopharma has published findings on recombinant trypsinogen and chymotrypsinogen in the journal Microbial Cell Factories. This research supports the development of rec-PRP, a backup clinical compound for treating metastatic cancer. The study indicates that these proenzymes can be produced at scale, potentially leading to effective treatments with a longer shelf life. The company aims to enter clinical trials for rec-PRP in early 2027.

-PPCB

Jul 7, 2026

PPCBPhases

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to support the Phase 1b clinical trial of its lead candidate, PRP, aimed at treating advanced solid tumors. The collaboration emphasizes a commitment to scientific rigor and patient safety. Avance Clinical will leverage its expertise to facilitate the trial's design and execution, aiming for efficient progression through clinical phases.

-PPCB

Jul 2, 2026

PPCBGeneral

▲ +22.9%on this newsshared move

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Propanc Biopharma has launched a $5 million share repurchase program, starting with an initial tranche of $500,000. CEO James Nathanielsz highlighted the company's belief in the transformative potential of its lead asset, PRP, for treating metastatic cancer. The program allows for flexible share buybacks based on market conditions and reflects the company's commitment to enhancing shareholder value.

-PPCB

Jun 16, 2026

PPCBPhases

▼ -10.2%on this news· ran to -31% by day 3

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma's CEO, James Nathanielsz, visited a European CDMO to prepare for GMP production of PRP for a Phase 1b study targeting advanced cancer patients. The visit aimed to solidify the partnership and discuss project timelines, including pre-production and engineering runs. The company anticipates submitting a clinical trial application in Australia in 2026.

-PPCB

Jun 11, 2026

PPCBGeneral

▲ +80%on this newsshared move

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma has announced a $5 million share repurchase program, reflecting its confidence in the company's intrinsic value. This decision comes as the company progresses its lead asset, PRP, towards a pivotal Phase 1b clinical trial for metastatic cancer. The FDA has granted Orphan Drug Designation for PRP, enhancing its market potential.

-PPCB

Jun 2, 2026

PPCBGeneral

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma's CEO, James Nathanielsz, attended a keynote address at the University of Granada, focusing on rejuvenation and health in an ageing society. The event featured Dr. Juan Carlos Izpisúa, a leading scientist in regenerative medicine. Propanc's ongoing research aims to develop treatments targeting age-related diseases, with their lead product PRP set to enter a Phase 1b study.

-PPCB

May 19, 2026

PPCBPhases

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma has engaged a European CDMO for GMP production of its lead asset, PRP, ahead of a Phase 1b, First-In-Human study targeting 30-40 advanced cancer patients. The therapy aims to induce differentiation in cancer cells rather than directly killing them, potentially offering a novel treatment approach. The company plans to file a clinical trial application later this year.

-PPCB

May 14, 2026

PPCBGeneral

▼ -21.4%on this newsshared move

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma has approved a 1-for-25 reverse stock split to comply with Nasdaq listing requirements. Effective May 18, 2026, the split will reduce the number of outstanding shares significantly. The company aims to enhance its market position and advance its lead product candidate, PRP, into a Phase 1b clinical study for advanced cancer patients.

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma has entered a multi-year research collaboration with the Universities of Jaén and Granada in Spain, focusing on anti-aging and cancer research. This partnership aims to evaluate a senescence-modulating compound and support claims related to recently filed patents. The collaboration is expected to enhance Propanc's intellectual property and advance its lead asset, PRP, towards clinical studies.

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma's lead asset, PRP, demonstrates over 85% tumor growth inhibition in preclinical pancreatic cancer models. The investigational therapy targets cancer stem cells and aims to improve treatment outcomes while minimizing side effects. With a Phase 1b trial slated for 2026, the company is optimistic about PRP's potential to redefine cancer care.

-PPCB

Feb 18, 2026

PPCBGeneral

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma has provided a corporate update and reported its half-yearly financial results for 2025/26. The company has filed four provisional patent applications to enhance its intellectual property portfolio and published research on the impact of proenzymes on pancreatic cancer. Additionally, a $100 million private placement has been secured to support clinical development, with plans for a Phase 1b study of its lead asset, PRP.

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma has introduced PRP, a novel proenzyme therapy aimed at treating pancreatic cancer. This therapy combines two pancreatic proenzymes and has shown promising results in preclinical studies, including significant tumor growth inhibition. PRP seeks to address the limitations of current cancer treatments by targeting cancer stem cells and minimizing side effects. The company plans to initiate a Phase 1b First-In-Human study in 2026.

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma has filed its fourth provisional patent application in two months, focusing on innovative formulations of pancreatic proenzymes. This move aims to strengthen its patent portfolio, potentially doubling it to over 200 patents. The company is preparing for a Phase 1b study of its lead asset, PRP, which targets cancer stem cells while minimizing toxicity. CEO James Nathanielsz emphasizes the significance of these patents in securing the company's leadership in cancer treatment.

-PPCB

Jan 20, 2026

PPCBGeneral

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma has filed a new provisional patent application for producing synthetic versions of trypsinogen and chymotrypsinogen, aimed at treating metastatic cancer. This innovative approach could lead to a world-first therapy with extended shelf-life and global distribution capabilities. The company is optimistic about its strategic plan and ongoing research into unmet medical needs.

-PPCB

Jan 16, 2026

PPCBPhases

▼ -10.8%on this news· ran to -24% by day 3shared move

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma has provided an update on its pancreatic cancer research, focusing on its lead candidate PRP, a mixture of pancreatic proenzymes. The FDA has granted PRP Orphan Drug Designation, highlighting the urgent need for effective treatments. The company plans to initiate Phase I/II clinical trials in 2026, targeting cancer stem cells and offering a potential new therapeutic option.

-PPCB

Jan 13, 2026

PPCBPhases

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma provided a shareholder update detailing its progress in 2025 and plans for 2026. The company aims to advance its lead asset, PRP, into a Phase 1b clinical study for advanced solid tumors. Propanc is also expanding its research into additional therapeutic areas and developing a synthetic backup compound, Rec-PRP. The CEO expressed confidence in the company's strategic roadmap and potential for growth.

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma has published significant findings on the effects of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts in a peer-reviewed journal. The study suggests that PRP, a treatment derived from bovine pancreatic proenzymes, may disrupt the tumor microenvironment and improve survival rates for patients. Future clinical trials are planned to further investigate PRP's efficacy as an adjunct therapy for advanced PDAC.

-PPCB

Dec 4, 2025

PPCBPhases

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma is set to explore 'mesenchymal drift' to develop treatments for chronic diseases, including cancer and fibrosis. The company's lead candidate, PRP, may influence critical biological processes linked to these conditions. A Phase 1b study for PRP is scheduled for 2026, aiming to assess its safety and efficacy in patients with advanced solid tumors.

-PPCB

Aug 14, 2025

PPCBGeneral

▲ +30%on this news· ran to -64% by day 1

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB Melbourne, Australia / Globe Newswire /

Propanc Biopharma, Inc. has announced the pricing of an underwritten public offering of 1,000,000 shares of common stock, priced at $4.00 per share, expected to yield approximately $4 million in gross proceeds. The company has also received approval to uplist its common stock on the Nasdaq Capital Market, with trading set to commence on August 15, 2025. The funds from the offering will be used for working capital and general business purposes. This marks a significant transition from OTC trading to a more prominent exchange.

-PPCB

Jun 24, 2019

PPCBGeneral

Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer CFO Adds Substantial Financial, Medical Technology and Senior Exchange Experience

Biopharma Appoints Carlo Campiciano as Chief Financial Officer Adds Substantial Financial, Medical Technology and Senior Exchange Experience Australia - June 24, 2019 - Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc", the "Company", "we", "our", or "us"), a biopharmaceutical co

-PPCB

Apr 10, 2018

PPCBGeneral

Propanc Biopharma Completes Scientific Advice Meeting with MHRA Company Receives Guidance on the Investigational Medicinal Product Manufacturing Program for

Biopharma Completes Scientific Advice Meeting with MHRA Receives Guidance on the Investigational Medicinal Product Manufacturing Program for PRP. AUSTRALIA, April 10, 2018-- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharma

-PPCB

Mar 14, 2018

PPCBGeneral

Propanc Biopharma Completes Successful Reproduction Run for PRP Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps MELBOURNE, AUSTRALIA

Biopharma Completes Successful Reproduction Run for PRP Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps AUSTRALIA, March 14, 2018-- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or the "Company"), a clinical stage biopharmaceutical compa

-PPCB

Feb 20, 2018

PPCBGeneral

Propanc Biopharma Receives Allowance of Key Patent Application in the EU Patent covers a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union MELBOURNE, AUS

Propanc Biopharma Receives Allowance of Key Patent Application Patent covers a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union MELBOURNE, AUSTRALIA, February 20, 2018- Propanc Biopharma Inc. (OTCQB: PPCB) ("

-PPCB

Mar 31, 2017

PPCBGeneral

Propanc Authorizes Reverse Stock Split

Propanc Authorizes Reverse Stock Split and Corporate Name Change to Propanc Biopharma, Inc. Reverse Split and Name Change to be Effectuated AUSTRALIA, March 31, 2017-- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company

-PPCB

Aug 23, 2016

PPCBGeneral

Propanc Enters into Contract Manufacturing Agreement with AmatsiQBiologicals Development and Production of PRP for Human Use in First-In-Man Studies MELBOURNE, AUSTRALIA

Propanc Enters into Contract Manufacturing Agreement with AmatsiQBiologicals Development and Production of PRP for Human Use in First-In-Man MELBOURNE, AUSTRALIA, August 23, 2016 - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or the "Company"), an emerging health

-PPCB

Jul 5, 2016

PPCBPhases

Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP Set to Initiate Development and GMP manufacture of Finished Drug Product for First-In-Man Studies MELBOURNE, AUSTRALIA

Propanc Receives Investment to Initiate GLP Safety Toxicology Set to Initiate Development and GMP manufacture of Finished Drug Product for First-In-Man Studies MELBOURNE, AUSTRALIA, July 5, 2016 - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an

-PPCB

Nov 17, 2015

PPCBGeneral

Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range MELBOURNE, AUSTRALIA, November 17 th , 2015 - Propanc He

Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range MELBOURNE, AUSTRALIA, November 17th, 2015 - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Com

-PPCB

Sep 22, 2014

PPCBGeneral

Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners MELBOURNE, AUSTRALIA

Propanc enters into $5 million Equity Purchase Agreement with MELBOURNE, AUSTRALIA, September 22, 2014 - Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc" or "the Company"), an emerging healthcare company that focuses on the development of new and proprietary treatments

-PPCB

Jun 27, 2012

PPCBGeneral

Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol

Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol PPCH MELBOURNE, Australia, June 27, 2012 - Propanc Health Group Corporation (OTCBB: PPCH), a developmental stage healthcare company focused on the development of new cancer treatments for patients with solid tum

Competitive Position

How PPCB ranks across every disease it competes in

Competitive Position is a premium feature

See how PPCB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$1.17

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Catalyst Timeline

Upcoming catalysts 2

Event history 2

Past FDA Catalysts & PDUFA Decisions

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in PPCB

PPCB Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Company News

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB Melbourne, Australia / Globe Newswire /

Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer CFO Adds Substantial Financial, Medical Technology and Senior Exchange Experience

Propanc Biopharma Completes Scientific Advice Meeting with MHRA Company Receives Guidance on the Investigational Medicinal Product Manufacturing Program for

Propanc Biopharma Completes Successful Reproduction Run for PRP Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps MELBOURNE, AUSTRALIA

Propanc Biopharma Receives Allowance of Key Patent Application in the EU Patent covers a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union MELBOURNE, AUS

Propanc Authorizes Reverse Stock Split

Propanc Enters into Contract Manufacturing Agreement with AmatsiQBiologicals Development and Production of PRP for Human Use in First-In-Man Studies MELBOURNE, AUSTRALIA

Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP Set to Initiate Development and GMP manufacture of Finished Drug Product for First-In-Man Studies MELBOURNE, AUSTRALIA

Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range MELBOURNE, AUSTRALIA, November 17 th , 2015 - Propanc He

Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners MELBOURNE, AUSTRALIA

Propanc to Begin Trading on the OTC Bulletin Board Under the Symbol

Competitive Position